腺病毒载体疫苗。
Adenovirus-vectored vaccines.
机构信息
International Centre for Genetic Engineering & Biotechnology, Recombinant Gene Products Group, PO Box 10504, Aruna Asaf Ali Marg, New Delhi-110067, India.
出版信息
Expert Opin Ther Pat. 2008 Mar;18(3):293-307. doi: 10.1517/13543776.18.3.293.
BACKGROUND
Engineered adenoviruses are being increasingly explored as immunoprophylactic or immunotherapeutic vaccine vectors. Encouraging data from preclinical studies using human adenovirus vectors carrying different antigen genes have resulted in many currently ongoing clinical trials.
OBJECTIVE
The article seeks to review the current status of the use of adenoviruses as vaccine vectors.
METHODS
This review is based on the patent literature since 2000 pertaining to the development of adenovirus vaccine vectors for infectious and non-infectious diseases.
CONCLUSION
Human adenovirus-vectored vaccines have important limitations that stem from their immunogenicity and restrict their utility. This has spurred intensive efforts to find alternative adenovirus vectors and strategies, each with its own advantages and shortcomings.
背景
工程化腺病毒作为免疫预防或免疫治疗疫苗载体正得到越来越多的探索。使用携带不同抗原基因的人腺病毒载体进行的临床前研究取得了令人鼓舞的数据，这导致了许多正在进行的临床试验。
目的
本文旨在综述腺病毒作为疫苗载体的应用现状。
方法
这篇综述基于 2000 年以来与开发腺病毒疫苗载体用于传染病和非传染病相关的专利文献。
结论
人腺病毒载体疫苗存在重要的局限性，这源于它们的免疫原性，并限制了它们的应用。这促使人们积极寻找替代腺病毒载体和策略，每种策略都有其自身的优缺点。
Zotero 插件